# An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic Infection

> **NCT02972450** · PHASE1,PHASE2 · TERMINATED · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 1 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **BIOLOGICAL:** GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine
- **BIOLOGICAL:** GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine+ Vedolizumab
- **DRUG:** Vedolizumab 300 MG [Entyvio]
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02972450
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-20
- **Primary completion:** 2019-07-11
- **Final completion:** 2019-07-11
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Due to the bankruptcy of FITBiotech, the provider of the GTU DNA vaccine.
- **Last updated:** 2019-08-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02972450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02972450, "An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic Infection". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02972450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*